Radiopharm Theranostics revenue was $1.98M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2026) ending on Jun 30, 2026 was N/A, down N/A from last quarter. For the last reported fiscal year 2026 ending Jun 30, 2026, RADX annual revenue was $1.9M, with -20% growth year-over-year.
RADX past revenue growth
How has RADX's revenue growth performed historically?
Radiopharm Theranostics (NASDAQ: RADX) reported Q2 2026 revenue of N/A up N/A year over year. In the same quarter last year, Radiopharm Theranostics's revenue was N/A.
What was Radiopharm Theranostics's revenue in 2026?
Radiopharm Theranostics's annual revenue for the twelve months ending Jun 30, 2026 was $1.91 million, a 19.98% decrease year over year.
How much does Radiopharm Theranostics make in a day?
Based on Radiopharm Theranostics annual revenue for the past five years, RADX makes an average of $2,573.27 per day.
What was Radiopharm Theranostics's annual revenue growth in the past year?
As of Q3 2026, Radiopharm Theranostics's revenue has grown -19.98% year over year. This is 293.1 percentage points lower than the US Biotechnology industry revenue growth rate of 273.12%. Radiopharm Theranostics's revenue in the past year totaled $1.98 million.
How much does Radiopharm Theranostics make in a year?
Radiopharm Theranostics's revenue by year for the past five years is:
Radiopharm Theranostics's revenue for the twelve months ending Jun 30, 2026 was $1.91 million, a 19.98% decrease year over year.
Radiopharm Theranostics's annual revenue for Jun 30, 2025 was $2.39 million, a 1,098.29% increase from 2024.
Radiopharm Theranostics's annual revenue for 2024 was $199.49 thousand, a 3.1% increase from 2023.
Radiopharm Theranostics's annual revenue for 2023 was $193.49 thousand, a Infinity% increase from 2022.
Radiopharm Theranostics's annual revenue for 2022 was $0.00, a N/A decrease from 2021.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.